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a b s t r a c t
StAP3 is a plant aspartic proteasewith cytotoxic activity toward a broad spectrumof pathogens, including
potato and human pathogen microorganisms, and cancer cells, but not against human T cells, human red
blood cells or plant cells. For this reason, StAP3 could be a promising and potential drug candidate for
future therapies. In this work, the improvement of the performance of StAP3 was achieved by means
of a modiﬁcation with PEG. The separation of a mono-PEGylated StAP3 fraction was easily performedntimicrobial protein
elective cytotoxicity
by gel ﬁltration chromatography. The mono-PEGylated StAP3 fraction was studied in terms of in vitro
antimicrobial activity, exhibiting higher antimicrobial activity against Fusarium solani spores and Bacillus
cereus, but slightly lower activity against Escherichia coli than native protein. Such increase in antifungal
activity has not been reported previously for a PEGylated plant protein. In addition, PEGylation did not
affect the selective cytotoxicity of StAP3, since no hemolytic activity was observed.
© 2014 Published by Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction
Antimicrobial proteins and peptides (AMPPs) are important
omponents of the natural defences against pathogens and are
ound in a wide range of eukaryotic organisms, from humans to
lants [1–6]. The discovery of new groups of AMPPs as potential
atural antibiotics represents a hit toward the discovery of a novel
eneration of drugs for the treatment of bacterial and fungal infec-
ions [7]. Moreover, the broad spectrum of antimicrobial activities
eported for these molecules suggests their potential beneﬁt in
he treatment of viral or parasitic infections [8,9] and cancer
10,11]. In contrast to conventional antibiotics, they act by physical
Abbreviations: AMPPs, antimicrobial proteins and peptides; ATCC, American
ype Culture Collection; BSA, bovine serum albumin; DTT, dithiothreitol; hRBC,
resh human red blood cells;mPEG-SVA, succinimidyl valeratemonomethoxy poly-
thylene glycol; PBS, phosphate buffered saline; PDA, potato dextrose agar; PEG,
olyethylene glycol; SDS, sodium dodecyl sulphate; SDS-PAGE, sodium dodecyl sul-
atepolyacrylamidegel electrophoresis;StAP3, Solanumtuberosumasparticprotease
; StAsp-PSI, plant-speciﬁc insert of potato aspartic protease.
∗ Corresponding author at: 3250 Funes, 4th Floor, Mar del Plata 7600, Argentina.
el.: +54 223 4753030 ext. 14; fax: +54 223 4724143.
E-mail address: gguevara@mdp.edu.ar (M.G. Guevara).
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2 These authors contributed equally to this paper.
ttp://dx.doi.org/10.1016/j.btre.2014.05.007
215-017X © 2014 Published by Elsevier B.V. Open access under CC BY-NC-ND license.disturbance or destruction of the barrier function of the plasma
membrane cell without involvement of a speciﬁc receptor [12,13].
Plants, unlike mammals, lack mobile defensive cells and a
somatic adaptive immune system. Instead, they rely on the innate
immunity of each cell and on systemic signals emanating from
infection sites [14–16]. In vitro antimicrobial activity has been
demonstrated for the following plant peptides and proteins: (i)
some of the so-called pathogenesis-related proteins, which were
originally identiﬁed as pathogen-elicited proteins [17,18]; (ii) a
number of plant antimicrobial protein and peptide families [19].
Furthermore, plant proteins and peptides with in vitro cytotoxic
activity and anticancer properties on human cancer cell lines
have also been reported [20–25]. We have previously reported
the induction after infection and the cytotoxic activity of potato
aspartic proteases (StAPs) toward plant pathogens [26–28]. Our
results show that potato aspartic proteases (StAPs) and their swa-
posindomain (StAsp-PSI) areproteinswith cytotoxic activitywhich
involvesplasmamembranedestabilization. Theabilityof thesepro-
teins to produce cell death varies with the cellular type [28–30].
We have demonstrated that the lack of hemolytic and cytotoxic
activities on human lymphocytes of StAsp-PSI/StAPs is attributed
to the presence of cholesterol in these cellmembrane types [29,31].
These results open a new perspective to test these proteins as pos-
sible candidates to develop new drugs that would be active against
microbes but not against mammalian cells and considerer these
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roteins as conceptually promising agent in infectious diseases and
ancer therapy.
The covalent attachment of polyethylene glycol (PEG) chains
PEGylation) to therapeutic peptides and proteins has become one
f the most useful pharmaceutical techniques developed thus far
o provide functional bioconjugates with improved therapeutic
roperties over their unmodiﬁed counterparts [32,33]. PEGylation,
ndeed, has beenproposed as amethod for optimizing pharmacoki-
etic and pharmacodynamic properties of therapeutic small drug
olecules, peptides and proteins [34]. The modiﬁcation leads to
n increase in molecular size and steric hindrance, changes in con-
ormation and electrostatic binding properties. This results in the
eduction of renal ultraﬁltration, the masking of proteolytic and
mmunogenic sites and the shielding from proteolytic enzymes,
ntibodies or antigen processing cells [34–36]. This strategy can
rolong the plasma circulating half-life, augment the in vivo stabil-
ty [34,37–40], and diminish the phagocytosis and immunogenicity
f peptides and proteins [36,41–43]. Due to these beneﬁts, PEGy-
ation plays an increasingly important role in the production of
nhanced peptide and protein delivery systems [44].
There are few works in which PEGylation is used to improve
lant proteins therapeutic potential, reducing their immunogenic
ehavior andextending thepermanenceof the injecteddrugs in the
ody. Examples of this include histaminase from Lathyrus sativus
hoots for alternative treatment of histamine-mediated affections
45]; -momorcharin and momordica anti-HIV protein derived
rom Momordica charantia L., for antitumor and antivirus thera-
ies [46,47]; pokeweed mitogen, a plant lectin able to enhance the
ytotoxicity of human lymphokine-activated killer cells [48]; and
ecombinant phenylalanine ammonia-lyase, originated from pars-
ey (Petroselinum crispum) for the treatment of phenylketonuria
49], among others [50–52].
In this work, the improvement of the performance of StAP3
as achieved by means of a covalent modiﬁcation with PEG. The
eparation of a mono-PEGylated StAP3 fraction could easily be
erformed by gel ﬁltration chromatography. The mono-PEGylated
tAP3 fraction was studied in terms of in vitro antimicrobial activ-
ty, exhibiting higher antimicrobial activity against Fusarium solani
pores and Bacillus cereus. In addition, PEGylation did not affect
he selective cytotoxicity of StAP3, since no hemolytic activity was
bserved.
. Materials and methods
.1. Materials and microorganisms
Succinimidyl valerate monomethoxy polyethylene glycol
mPEG-SVA, 5 kDa) was purchased from Laysan Bio Inc. (Arab,
L, USA). Sodium dodecyl sulphate (SDS) and dithiothreitol (DTT)
ere supplied by Sigma (St. Louis, MO, USA). All the reagents
ere purchased in the highest purity and used without further
uriﬁcation.
F. solani f. sp. eumartii, isolate 3122 (EEA-INTA, Balcarce,
rgentina)was grown at 25 ◦C on potato dextrose agar (PDA) plates
upplemented with 100g/ml ampicillin. Spores were collected
rom 8-day-old cultures by suspension in sterile water.
B. cereus and Escherichia coli were provided by the American
ype Culture Collection (ATCC) and were grown in Luria–Bertani
edium at 37 ◦C with continuous shaking. Bacterial growth was
uantiﬁed by measuring absorbance at 600nm.
.2. Protein puriﬁcation and preparation of PEG-StAP3
PEGylated-StAP3)
Potato leavesweredetachedandplacedat18 ◦C inamoist cham-
er. StAP3 was puriﬁed from leaves using the protocol previouslyy Reports 3 (2014) 1–7
described by Guevara et al. [53]. A solution of puriﬁed StAP3 (5ml,
0.6mg/ml) in 50mM Tris–HCl pH 8, was added to a 40-fold molar
excess of mPEG-SVA. The mixture was incubated at 25 ◦C with stir-
ring at 500 rpm, and the reactionwasquenchedafter 6hbyaddition
of 2ml 1M glycine solution. The mixture was then concentrated
to 230l using Vivaspin 15R (MW cut-off 5 kDa) (VIVASCIENCE,
Germany), and 0.4% SDS (w/v) and 0.2mM DTT were added.
2.3. Size exclusion chromatography (SEC)
PEG-StAP3 conjugates were analyzed by size exclusion chro-
matography on an equilibrated Superose 12 HR (10/30) column
(Pharmacia, Uppsala, Sweden), connected to a fast-protein liq-
uid chromatography system, at a constant ﬂow rate of 0.4ml/min
at room temperature. The column was calibrated using a mix-
ture of four proteins of known molecular mass, i.e. pyruvate
kinase (230kDa), native StAP3 (45kDa), glyceraldehyde-3P-
dehydrogenase (36kDa), and lysozyme (14.3 kDa). The columnwas
equilibrated and eluted with 20mM Tris–HCl pH 8, 0.4% SDS (w/v),
and 0.2mM DTT. Fractions of 0.4ml were collected and the elution
was monitored at 280nm.
2.4. Gel electrophoresis
Fractions from the size exclusion chromatography correspond-
ing to different peaks were pooled and then analyzed by SDS-PAGE
using 12% acrylamide. Gel was stained with Coomassie Brilliant
Blue R250 coloidal [54]. Samples were treated in denaturing buffer
with SDS, -mercaptoethanol and heated before SDS-PAGE.
2.5. Analytical procedures for protein quantiﬁcation
Protein concentration was measured by the Bradford method
[55], using BSA as the standard.
2.6. Functionality assays
The fraction containing mono-PEG-StAP3 species was the
employed for biological studies. Prior to assays, this fraction was
dialyzed against 20mM Tris–HCl pH 8, for 48h at 4 ◦C, using a cel-
lulose membrane (Sigma D9652-100) to remove DTT and SDS. The
fraction was then stored at −20 ◦C for further analyses.
2.6.1. Cytotoxic activity assays
To evaluate the effect of mono-PEG-StAP3 on the germination
of F. solani spores, in vitro bioassays were performed as described
by Guevara et al. [26]. To quantify the effect of mono-PEG-StAP3 on
spore germination, the bioassays were examined by observation
of four ﬁelds in Neubauer camera with a bright-ﬁeld microscope.
The results from three independent experiments were analyzed to
calculate the percentage of inhibition.
B. cereus and E. coli were grown in Luria–Bertani medium at
37 ◦C with continuous shaking to exponential phase. The bacte-
ria were harvested from broth by centrifugation at 3500 rpm for
10min, washed and resuspended in sterile PBS at a concentra-
tion of 104 c.f.u./ml. The concentration of bacteria was veriﬁed
and quantiﬁed by culture on sheep blood agar plates. One hun-
dred microliters of bacterial suspension were plated on 96-well
polystyrene microtiter plates (BD Biosciences), and serial dilutions
of mono-PEG-StAP3 were added to individual wells in triplicate
and incubated for 6h at 37 ◦C with rocking. Bacteria were subse-
quently dispersed and aliquots were plated on blood agar plates to
obtain colony counts. Pathogen viability after protein treatment
was determined from the number of colonies obtained on the
buffer-treated control plates compared to the number of colonies
nology Reports 3 (2014) 1–7 3
f
c
r
2
m
a
a
u
q
3
w
J
i
w
r
w
o
v
2
t
t
s
w
o
1
b
a
t
3
3
i
a
u
o
9
t
T
m
p
P
p
P
t
a
a
e
f
P
p
i
i
[
h
t
t
t
s
Fig. 1. Separation of PEG-StAP3 species. (A) Size exclusion chromatography. The
upper panel shows the calibration curve as well as the elution times of the different
peaks obtained after StAP3 PEGylation reaction. Elution times of proteins used for
calibration are indicated by solid symbols, and elution times of StAP3-PEGylated
species are indicated by open symbols. The lower panel contains the elution proﬁle
of PEG-StAP3 species from Superose 12 HR 10/30 column. Experiments were per-
formed with 20mM Tris–HCl pH 8, in the presence of 0.4% SDS (w/v) and 0.2mM
DTT. Absorption (arbitrary units, AU) was measured at 280nm. (B) SDS-PAGE 12%F. Mun˜oz et al. / Biotech
rom protein-treated samples. The half maximal inhibitory con-
entration (IC50) was calculated as the concentration of protein
equired to inhibit microbial growth by 50%.
.6.2. Cell membrane permeabilization ability of
ono-PEG-StAP3
F. solani spores were incubated overnight at 25 ◦C with water
s control or exposed to different amounts of mono-PEG-StAP3,
s described by Guevara et al. [26]. SYTOX Green probe (Molec-
lar Probes) was added to a ﬁnal concentration of 0.5M and
ualitative detection of SYTOX Green uptake was performed. After
0min incubation, the ﬂuorescence of the sample was observed
ith a Nikon Eclipse E200 ﬂuorescence microscope (Nikon, Tokyo,
apan) equipped with a B-2A Fluorescein ﬁlter set. Positive controls
ncluded spores treatedwith0.5% (w/w)TritonX-100. Fluorescence
as measured using a FluorosKan Ascent (Thermo Electron Corpo-
ation, Finland) ﬂuorescence measurement system at an excitation
avelength of 480nm and an emission wavelength of 530nm. Flu-
rescence values were corrected by subtracting the ﬂuorescence
alue of a buffer incubated with SYTOX Green.
.6.3. Hemolysis assay
Fresh human red blood cells (hRBC) were rinsed in PBS, cen-
rifuged for 10min at 800 rpm three times, and resuspended in PBS
o a ﬁnal erythrocyte concentration of 4% (v/v). The hRBC suspen-
ion (100l)was added to a 96-wellmicrotiter plate and incubated
ith different concentrations of mono-PEG-StAP3 in PBS. Controls
f zero and100%hemolysis consistedof hRBC suspended inPBS and
% (w/w) Triton X-100, respectively. These suspensions were incu-
ated with agitation for 3h at 37 ◦C. The samples were centrifuged
t 800 rpm for 10min, and the release of hemoglobin was moni-
ored by measuring the absorbance of the supernatant at 550nm.
. Results and discussion
.1. StAP3 PEGylation
Native StAP3 was incubated with mPEG-SVA (1:40 molar ratio)
n 50mM Tris–HCl pH 8, and the obtained conjugated species were
nalyzed by size exclusion chromatography after quenching the
nreacted PEGylating agent with glycine (Fig. 1A). Four peaks were
btained, corresponding to molecular weights of approximately
0kDa, 74kDa, 60kDa, and 45kDa, which could be associated to
he different species through gel electrophoresis assay (Fig. 1B).
he analysis suggested that the pool of peak 1 is the result of a
ixture of mainly tri- and di-PEGylated species to a lesser extent;
eak2containsdi-PEGylated specieswitha lower contentofmono-
EGylated species; peak 3 consists inmono-PEGylated species; and
eak 4 contains native StAP3 protein. The yield of puriﬁed mono-
EGylated fraction, as determined by SEC considering the ratio of
he peak areas, was found to be 46.14% of the total protein, whereas
5.06% remained as native protein. The relative abundance of di-
nd tri-PEGylated species could not be determined. The appar-
nt molecular weight of the different PEGylated species obtained
rom size exclusion chromatography and gel electrophoresis (SDS-
AGE) is overestimated due to the retarded mobility of PEGylated
roteins, which has been previously reported [56,57]. Moreover,
t has also been reported that a 5kDa-PEG-conjugated protein
ncreases its apparent molecular weight in 15kDa approximately
58]. This phenomenon has been attributed to the fact that the
ydrodynamic volume for a PEG-conjugated protein results higher
han the expected for a protein of similar molecular weight, due to
he high hydrophilicity of the PEG unit [59,60].
Taking into account the results previously described we suggest
hat a pool of mono-PEG-StAP3 free of higher-degree PEGylated
pecies and native StAP3 could be obtained from peak 3 as the mostanalysis of fractions from the various columnpeaks. Each lane corresponds to a peak
fraction as follows: Lane 1, peak 1; Lane 2, peak 2; Lane 3, peak 3; and Lane 4, peak
4. Gel was stained with Coomassie Brilliant Blue R250 coloidal.
abundant fraction. However, given that StAP3 native protein con-
tains 30 l-lysine units [27], many of which are sterically available
for PEGylation, this pool is composedof different positional isomers
where PEGylation occurred in different -amino functional groups
besides -amino terminal group. Although it has been reported
that random PEGylation can lead to great loss of bioactivity [61,62],
the simplicity of production of this mono-PEG-StAP3 pool led us to
evaluate its biological properties in comparison to those of native
StAP3.
3.2. Effect of mono-PEG-StAP3 on the viability of pathogen spores
In order to analyze the effect of PEGylation on the in vitro
antimicrobial activity of StAP3, different amounts of mono-PEG-
StAP3 fraction were incubated with spores of a potato pathogen,
F. solani. Fig. 2 shows that mono-PEG-StAP3 was able to reduce F.
solani spore germination in a dose-dependent manner. As shown
in Table 1, the concentration of mono-PEG-StAP3 needed to reduce
50% spore germination (9g/ml) was almost 3-fold lower than the
previously reported fornative StAP3 (28g/ml) in the same incuba-
tion conditions [28]. These results denote that PEGylation increases
4 F. Mun˜oz et al. / Biotechnology Reports 3 (2014) 1–7
Fig. 2. Effect of mono-PEG-StAP3 fraction on spores of F. solani. F. solani spores (2.7×106 spores/ml) were incubated with different concentrations of mono-PEG-StAP3 ()
or native StAP3 () [28] for 16h at 25 ◦C and 100% relative humidity. After incubation, the number of spores germinated was evaluated under a light microscope by counting
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ptake. Data reported are the means of three experiments and error bars represent
ytotoxicity of StAP3 on spores of F. solani. This behavior has not
een previously observed for plant proteins as far aswe know, but a
imilar activity has also been reported by Lee et al. [38] for a recom-
inant antifungal insect protein. PEGylated recombinant tenecin 3
isplayed a greater antifungal activity againstCandida albicans than
he native protein at the same dose, suggesting a higher interaction
ith fungi cell walls.
.3. Effect of mono-PEG-StAP3 on pathogen plasma membrane
ntegrity
We have previously reported that the antimicrobial activity of
tAPs is associated to the ability of these proteins to induce changes
n the permeability of the microbial plasma membrane [28]. Based
n this fact, we investigated whether PEGylation alters the capac-
ty of StAP3 topermeabilizemicrobial plasmamembranes. An assay
ased on the uptake of the ﬂuorogenic dye SYTOX Green was used
63]. SYTOX Green can only penetrate cells that have compro-
ised plasma membranes, and it ﬂuoresces upon binding to DNA.
his assay was performed incubating F. solani spores with differ-
nt amounts of mono-PEG-StAP3 fraction in the same conditions
eported for antifungal activity [26]. SYTOX Green was then added
o evaluate membrane integrity by ﬂuorescence quantiﬁcation and
icroscopic examination. The ﬂuorescent probe was incorporated
nto the microbial spores in the presence of different amounts of
ono-PEG-StAP3 inadose-dependentmanner (Figs. 2 and3). These
esults indicate that thePEGylatedproteinwasable to inducemem-
ranepermeabilization in spores of F. solani in addition to cell death
s native StAP3, and moreover, that PEGylation increases StAP3
ytotoxic activity and plasma membrane disruption ability.
Imura et al. have reported that the antimicrobial tachyplesin
peptides induce membrane disruption through the formation
f toroidal pores. Moreover, it was found that PEGylation does
able 1
n vitro antimicrobial activity of mono-PEG-StAP3 fraction.
Treatment IC50 (g/ml)a
F. solani B. cereus E. coli
Mono-PEG-StAP3 9 ± 1.2 13.2 ± 2.3 96.2 ± 5.3
Native StAP3 [30] 28 ± 0.7 56.2 ± 0.9 58.5 ± 1.5
a Means± SD for at least three assays for each protein. The IC50 is the concentra-
ion of protein required to inhibit microbial growth by 50%.ith mono-PEG-StAP3 () or native StAP3 (©) [28] was detected by SYTOX Green
andard deviation.
not alter the basic mechanism of membrane permeabilization of
the parent peptide [64]. On the other hand, we have previously
reported that StAsp-PSI insertion into the membrane interface
and its aggregation lead to the disruption of the membrane by
a barrel-stave pore formation [31]. In addition, to determine
if the mechanism of membrane permeabilization occurring for
StAP3 is altered due to PEGylation further biophysical analyses
such as differential scanning calorimetry, infrared spectroscopy,
nuclear magnetic resonance and circular dichroism should be
performed.
3.4. Effect of mono-PEG-StAP3 on the viability of human bacterial
pathogens and erythrocytes
Previously, we demonstrated that StAPs are able to kill human
pathogenic bacteria in a dose-dependent manner, but are not toxic
to hRBC [30]. To determine whether PEGylation affects the bacte-
ricidal activity of StAP3, cultures of the Gram-positive bacterium
B. cereus and Gram-negative E. coli were incubated with increas-
ing concentrations of mono-PEG-StAP3 fraction for 6h at 37 ◦C.
Results obtained here show that mono-PEG-StAP3 was able to kill
bacterial cells in a dose-dependent manner (Fig. 4). The antibac-
terial activity of mono-PEG-StAP3 was more effective against B.
cereus than E. coli. The IC50 values were approximately 13.2 and
96.2g/ml mono-PEG-StAP3, respectively (Table 1). The IC50 val-
ues of mono-PEG-StAP3 were approximately 4 times lower on
B. cereus, and approximately 1.6 times higher on E. coli com-
pared to the StAP3 native form [30]. The greater susceptibility of
mono-PEG-StAP3’s antimicrobial effect on B. cereus compared to
E. coli may be accounted for the bacterial cell membrane com-
position. Gram-negative bacteria have a cytoplasmatic membrane
and an additional outer membrane that surrounds the cell, provid-
ing a barrier to mono-PEG-StAP3, whereas Gram-positive bacteria
have only cytoplasmatic membrane [65,66]. In comparison, PEGy-
lation of antimicrobial peptides tachyplesin I, nisin, -defensin,
and magainin with 5kDa PEG chains led to a drastic decrease or
even a complete loss of their antibacterial activities [64,67–69].
Nevertheless, the extent of the reduction in activity is strongly
dependent on the peptide/protein evaluated. It is possible that
mono-PEG-StAP3 decreases its ability to efﬁciently permeate the
outer membrane due to a large steric hindrance of the PEG moiety,
similar to that reported for PEGylated tachyplesin I and magainin
[64,68].
F. Mun˜oz et al. / Biotechnology Reports 3 (2014) 1–7 5
Fig. 3. Membrane permeabilization induced in spores of F. solani after incubating with mono-PEG-StAP3 fraction, detected by SYTOX Green uptake. Spores of F. solani were
incubated with the amount of protein required to completely inhibit germination. After 30min incubation in the presence of 0.5M SYTOX Green, the ﬂuorescence was
detected by ﬂuorescence microscopy. Panels 1–3: ﬂuorescence microscopy; panels 4–6, li
5, 85g/ml of mono-PEG-StAP3; panels 3 and 6, 168g/ml of native StAP3 [28]. Bars, 15
Table 2
Effect of mono-PEG-StAP3 fraction on human red blood cells.
Treatment Concentration (g/ml) Hemolysis of hRBC (%)
Triton X-100 100
Buffer 0.30±0.28
Mono-PEG-StAP3
11.25 0.35±0.03
225 0.62±0.20
450 1.30±0.50
1125 2.50±0.67
Native StAP3 [30]
11.25 0.70±0.12
225 1.20±0.34
450 2.00±0.53
1125 3.2±0.33
Fresh human red blood cells (hRBC) were incubated with different concentra-
tions of mono-PEG-StAP3 dissolved in PBS. Controls of zero and 100% hemolysis
consisted of hRBC suspended in PBS and 1% (w/w) Triton X-100, respectively. The
release of hemoglobin was monitored by measuring the absorbance of the super-
natant at 550nm. Values represent the media of three independent experiments
(means± SD).
F
c
p
dig. 4. Bactericidal activity of mono-PEG-StAP3 fraction on human pathogens. Different a
ereus or (B) E. coli cells (104 c.f.u./ml) in 100l of sterile PBS for 6h at 37 ◦C with rocking.
lates as compared to the number of colonies from protein-treated samples. Results are
eviation.ght-ﬁeld microscopy. Panels 1 and 4, control in the presence of water; panels 2 and
m.
Some antimicrobial peptides such as melittin, gramicidin S,
CaLL, and surfactant protein B are also cytotoxic to mammalian
cells, e.g. erythrocytes [70–73]. Therefore, only antimicrobial pep-
tides/proteins and their derivativeswithhighantimicrobial activity
and low cytotoxicity to the healthy eukaryotic cells are of prac-
tical interest. The hemolytic activity of mono-PEG-StAP3 fraction
was tested in vitro on hRBC to investigate whether PEGylation
affects the selective cytotoxicity of StAP3. As shown in Table 2,
mono-PEG-StAP3 did not show signiﬁcant hemolytic activity at all
concentrations assayed.
Several reports relate the hemolytic activity of antimicrobial
peptides with their capacity to strongly interact with either
membranes, containing cholesterol or not [74,75]. As for the
case of antimicrobial peptides unable to lyse red blood cells [76],
the presence of cholesterol into the LUVs membranes strongly
diminishes the capacity of StAsp-PSI to produce leakage at all
concentration assayed [29]. The presence of cholesterol in the
membranes causes a reduction in the density of hydrophilic head
groups at the interfacial region of the bilayer and an increase in
the packaging of the phospholipid tails in the middle of the bilayer
[77]. Despite this, the high rate of hydration of phospholipid head
group at the interface bilayer region found in cholesterol-rich
membranes does not allow the hydrophilic mono-PEG-StAP3 to
mounts of mono-PEG-StAP3 () or native StAP3 () [30] were incubated with (A) B.
c.f.u. were counted from the number of colonies obtained on buffer-treated control
representative of four separate experiments and error bars represent the standard
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isplay any hemolytic activity, as well as the more hydrophobic
ative StAP3. This result suggests that PEGylation does not affect
he selective cytotoxic activity reported for native StAP3 [30,78].
uture assays using calorimetry, infrared and NMR should be
erformed to corroborate this hypothesis.
. Conclusions
In this work a covalent modiﬁcation of StAP3 by PEGylation
as carried out. By size exclusion chromatography it was pos-
ible to isolate a main fraction of mono-PEGylated species. The
ytotoxic activity of this fraction was examined and compared to
hat of native protein. It is well known that the in vitro activity of
roteins decreases with PEGylation [39]. However, the mono-PEG-
tAP3 fraction displayed an enhanced in vitro antifungal activity
espect native StAP3 toward F. solani spores. This is the ﬁrst time
hat a PEGylated plant protein was found to present a higher cyto-
oxic activity against a pathogen than the native protein. This
as ascribed to a higher interaction between fungi cell walls and
he conjugated protein. On the other hand, PEGylation was found
o reduce antibacterial activity toward Gram-negative bacterium,
robably because outer membrane mainly acts as a mechanism
f antimicrobial resistance. In addition, PEGylation did not affect
he selective cytotoxicity of StAP3, since no hemolytic activity was
bserved. However, in vivo assays involving native StAP3 andPEGy-
ated forms are being carried out to test them as new agents in
herapy of infectious diseases and cancer, and will be published
lsewhere.
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